Sylvain A Lother1, Natasha Press2. 1. Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, University of British Columbia, 452D, Heather Pavilion East, VGH, 2733 Heather Street, Vancouver, BC, V5Z 3J5, Canada. sa.lother@me.com. 2. Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, University of British Columbia, 452D, Heather Pavilion East, VGH, 2733 Heather Street, Vancouver, BC, V5Z 3J5, Canada.
Abstract
PURPOSE OF THE REVIEW: Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a common cause of morbidity and mortality. First-line treatment requires frequent daily doses of an anti-staphylococcal beta-lactam. However, some physicians prescribe simpler once-daily regimens to improve compliance and improve healthcare utilization. We reviewed the literature regarding advantages, pitfalls, and efficacy of once-daily treatment options for MSSA bacteremia. RECENT FINDINGS: Several once-daily antibiotics are effective in vitro against MSSA (ceftriaxone, daptomycin, telavancin, dalbavancin, oritavancin, tedizolid, ertapenem, fluoroquinolones, and others), but there is insufficient evidence to support these agents for MSSA bacteremia. Ceftriaxone may be considered for therapy completion with MSSA bacteremia from osteomyelitis, and daptomycin may be considered in patients who cannot tolerate first-line therapy. However, they have not been compared to traditional second-line agents, and their role remains uncertain. Current evidence does not support the use of once-daily treatment options for MSSA bacteremia.
PURPOSE OF THE REVIEW: Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a common cause of morbidity and mortality. First-line treatment requires frequent daily doses of an anti-staphylococcal beta-lactam. However, some physicians prescribe simpler once-daily regimens to improve compliance and improve healthcare utilization. We reviewed the literature regarding advantages, pitfalls, and efficacy of once-daily treatment options for MSSA bacteremia. RECENT FINDINGS: Several once-daily antibiotics are effective in vitro against MSSA (ceftriaxone, daptomycin, telavancin, dalbavancin, oritavancin, tedizolid, ertapenem, fluoroquinolones, and others), but there is insufficient evidence to support these agents for MSSA bacteremia. Ceftriaxone may be considered for therapy completion with MSSA bacteremia from osteomyelitis, and daptomycin may be considered in patients who cannot tolerate first-line therapy. However, they have not been compared to traditional second-line agents, and their role remains uncertain. Current evidence does not support the use of once-daily treatment options for MSSA bacteremia.
Authors: Ursula C Patel; Erin L McKissic; Douglas Kasper; Joseph R Lentino; Constance T Pachucki; Todd Lee; Bert K Lopansri Journal: Int J Clin Pharm Date: 2014-09-04
Authors: Guy E Thwaites; Jonathan D Edgeworth; Effrossyni Gkrania-Klotsas; Andrew Kirby; Robert Tilley; M Estée Török; Sarah Walker; Heiman Fl Wertheim; Peter Wilson; Martin J Llewelyn Journal: Lancet Infect Dis Date: 2011-03 Impact factor: 25.071
Authors: Anthony D Bai; Adrienne Showler; Lisa Burry; Marilyn Steinberg; Daniel R Ricciuto; Tania Fernandes; Anna Chiu; Sumit Raybardhan; Michelle Science; Eshan Fernando; George Tomlinson; Chaim M Bell; Andrew M Morris Journal: J Antimicrob Chemother Date: 2015-01-21 Impact factor: 5.790
Authors: Martin E Stryjewski; Donald R Graham; Samuel E Wilson; William O'Riordan; David Young; Arnold Lentnek; Douglas P Ross; Vance G Fowler; Alan Hopkins; H David Friedland; Steven L Barriere; Michael M Kitt; G Ralph Corey Journal: Clin Infect Dis Date: 2008-06-01 Impact factor: 9.079
Authors: G Ralph Corey; Heidi Kabler; Purvi Mehra; Sandeep Gupta; J Scott Overcash; Ashwin Porwal; Philip Giordano; Christopher Lucasti; Antonio Perez; Samantha Good; Hai Jiang; Greg Moeck; William O'Riordan Journal: N Engl J Med Date: 2014-06-05 Impact factor: 91.245
Authors: K J Shaw; S Poppe; R Schaadt; V Brown-Driver; J Finn; C M Pillar; D Shinabarger; G Zurenko Journal: Antimicrob Agents Chemother Date: 2008-10-06 Impact factor: 5.191
Authors: Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett Journal: Clin Infect Dis Date: 2010-01-15 Impact factor: 9.079
Authors: R Andrew Seaton; Armando Gonzalez-Ruiz; Kerry O Cleveland; Kimberly A Couch; Rashidkhan Pathan; Kamal Hamed Journal: Ann Clin Microbiol Antimicrob Date: 2016-03-15 Impact factor: 3.944
Authors: Andi Rofian Sultan; Mehri Tavakol; Nicole A Lemmens-den Toom; Peter D Croughs; Nelianne J Verkaik; Annelies Verbon; Willem J B van Wamel Journal: PLoS One Date: 2022-02-16 Impact factor: 3.240